Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

240
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
240
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Inhaled Medications01:23

Inhaled Medications

237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

361
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
361
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

249
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
249

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanosensitive Piezo Channels Contribute to Airway Changes in Chronic Obstructive Pulmonary Disease.

bioRxiv : the preprint server for biology·2026
Same author

The Iron Lung: Ferroptosis and Iron Regulation in Aging and Lung Diseases.

Physiology (Bethesda, Md.)·2026
Same authorSame journal

Hyperoxia and iron homeostasis in developing human airway smooth muscle.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Loss of miRNA-153 promotes EndMT and compromises lung vascular integrity.

American journal of respiratory cell and molecular biology·2026
Same author

Targeting Hyperoxia-Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants.

Aging cell·2026
Same author

Stretch, Piezo channels, and store operated calcium entry in developing human airway smooth muscle.

Pediatric research·2026
Same journal

Early Dysanapsis in Experimental Bronchopulmonary Dysplasia: Implications for Lifelong Lung Disease.

American journal of physiology. Lung cellular and molecular physiology·2026
Same journal

Alternative splicing of Toll-like receptor pathway mRNAs in lung immune cells from patients with ARDS.

American journal of physiology. Lung cellular and molecular physiology·2026
Same journal

The Role of Estrogen Receptors and House Dust Mite-Induced DNA Methylation in a Mouse Model.

American journal of physiology. Lung cellular and molecular physiology·2026
Same journal

Macrophage in the Crosshairs: Chemical Inhalation and Lung Immune Defense.

American journal of physiology. Lung cellular and molecular physiology·2026
Same journal

Hormonal influences on asthma phenotypes and endotypes during the menopausal transition.

American journal of physiology. Lung cellular and molecular physiology·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K

Nanoparticles to target asthma.

Samantha K Hamrick1, Michael A Thompson1, Vincent M Rotello2

  • 1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, United States.

American Journal of Physiology. Lung Cellular and Molecular Physiology
|October 29, 2024
PubMed
Summary
This summary is machine-generated.

Nanoparticles offer a promising new approach for targeted asthma therapy, overcoming delivery challenges in the airways. Further research into nanoparticle safety and design is crucial for effective treatment of this chronic lung disease.

Keywords:
asthmalung diseasenanoparticlestherapeutic target

More Related Videos

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
11:26

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles

Published on: June 8, 2012

19.8K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.0K

Related Experiment Videos

Last Updated: Jun 9, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K
Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
11:26

Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles

Published on: June 8, 2012

19.8K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.0K

Area of Science:

  • Pulmonary Medicine
  • Nanotechnology
  • Pharmacology

Background:

  • Asthma affects 340 million globally, characterized by airway hyperresponsiveness, remodeling, and mucus.
  • Current asthma treatments have side effects and are ineffective for some patients, necessitating novel therapies.
  • Targeted drug delivery to specific airway cells is needed to overcome mucus and thickening.

Purpose of the Study:

  • To review the current applications of nanoparticles (NPs) in asthma treatment.
  • To identify opportunities for improving NP design and utilization for asthma.
  • To assess the potential of NPs as delivery systems and therapeutics for asthma.

Main Methods:

  • Review of current literature on nanoparticle use in asthma.
  • Analysis of NP characteristics (material, size, charge, surface modification) for drug delivery.
  • Evaluation of NP safety, including inflammation, toxicity, and organ accumulation.

Main Results:

  • Nanoparticles are highly customizable for delivering various therapeutic cargoes (nucleic acids, proteins, small molecules).
  • NPs show potential as therapeutics themselves for asthma.
  • Ongoing clinical trials and FDA-approved NP therapeutics suggest potential safety and efficacy.

Conclusions:

  • Nanoparticles represent a promising solution for targeted asthma therapy, addressing delivery challenges.
  • Careful consideration of NP safety profiles is essential for clinical translation.
  • Further optimization of NP design and application is needed for effective asthma management.